Penny Pinchers - CAT news

Item	Date	Source & Article
1	15 April	Saturday Telegraph: When I first became aware of CAt its share price had halved. At its peak it was £48.19. Its now well on its way back up. The reason for the drop in share price is explained in the article but I really don't understand. The upshot is it has now sorted itself out and doesn't have to face the market for 3 years. A number of drugs are in the pipeline the most advanced is due for launch in late 2002. Its arthritis treatment is in Phase III. Its a recommeded buy.
2	13th June 2000	Regulatory News Service (RNS) :: In April 5 directors purchased a total of 1794 shares in the company at the price of 1850p each representing a total investment of £33,189.
3	22nd May 2000	Cambridge Antibody sees rise in H2 opg expenditure, 'significant growth' LONDON (AFX) - Cambridge Antibody Technology Group PLC said it expects operating expenditure to rise in the second half of the year as the scale of activity is increased, However, investment income will be significantly higher, reflecting the increased level of cash and liquid resources. The company said it is now well positioned -- in terms of its financial base, its technology platform and its clinical programmes -- to achieve significant growth in the future. For the first six months to March 31 Cambridge Antibody reported a pretax loss of 2.1 mln stg against a loss for the previous first half of 6.46 mln. Turnover was 6.39 mln compared with nil the year before. Cambridge Antibody said it substantially strengthened its financial base during the period, including raising 93 mln stg before expenses from an equity fundraising. Since the period end the company issued 1.67 mln shares to HGS for 34.7 mln stg in cash, in connection with a collaboration agreement. In early April, on completion of the equity fund raising, 5.01 mln shares were issued to raise 89.5 mln stg net of expenses. Following the success of this financing, Cambridge Antibody said it intends to seek a secondary listing on the U.S. Nasdaq "at the appropriate time". The company said it is currently recruiting more staff and intends to build staff numbers from 153 at end March to approximately 250, with the greater part of the increase in the next 18 months. jfb
4	9 Oct 2000	AFX-Focus) 2000-10-09 15:06 GMT: Cambridge Antibody says Janus Capital sells 7.90 pct shareholding
5	14th Oct 2000	FT:CAMBRIDGE ANTIBODY TECH. GRP Directors Dealings: 180K SOLD by 3 directors for £7.38m.
6	23 Dec 2000	FT: Directer Sales: 32500 shares for a mere £1,332,500 for just one greedy director - looks like he will have a good Christmas anyway.
7	4 Dec 2000	4/12/00 14:19 GMT Cambridge Antibody, Zyomyx to jointly develop high-density protein biochips LONDON (AFX) - Cambridge Antibody Tech Group PLC said it has entered into a collaborative agreement with Zyomyx Inc to develop high-density protein biochips based on antibody arrays. Under the agreement, Zyomyx and CAT will jointly develop parallel antibody arrays for the detection of proteins from complex biological mixtures, it added. CAT will supply human antibody fragments from its proprietary phage display libraries and Zyomyx will provide technology and know-how in protein biochip systems, it said.
8	25 Jan 2001	25/1/01 07:29 GMT Cambridge Antibody, Elan in neurological disorder treatment tie-up LONDON (AFX) - Cambridge Antibody Technology Group (CAT) PLC and Elan Corp have entered into a strategic partnership committed to the development of novel therapeutics for the treatment of human neurological disorders, the companies said in a joint statement. They will jointly discover and develop antibody-based therapeutics targeted at a variety of neurological diseases and disorders, the statement said. Under the terms of the four year agreement, the two companies will fund all research and development jointly and share commercialisation profits equally, it said. CAT will have primary responsibility for the discovery and optimisation of human antibodies against multiple targets identified by Elan, they said, adding they have have already identified over 40 targets in the field that will immediately become the focus of this alliance.
9	5 Feb 2001	©2001 citywire.co.uk18:34, Mon 5 Feb 2001:CAT boss sells more shares The non-executive chairman of Cambridge Antibody Technology has cut his holding days after it announced collaboration with Irish pharmaceutical group Elan. Peter Garland sold 3,667 Cambridge Antibody (CAT) shares today at £32.10, pocketing £117,000 in the process[looks like he's doing better than us!-IRW]. He also transferred 5,500 shares to his adult children, reducing his holding in the company to 41,166 shares in the £1.1 billion company. CAT's shares rallied today, closing up 155p at £32.30p, but are still well down on last March's high when the tech bonanza took them to £48.19. They went as low as £18.83 in the correction. CAT announced on 26 January that it had agreed a partnership with Elan to discover new drugs to treat neural disorders. The company will provide Elan with antibodies from its antibody library to attack the molecules it identifies as being responsible for neurological diseases. Elan will uses genomics - the study of role played by genes in causing diseases - to identify such molecules. The company announced a similar deal in December with US firm Immunex to develop human monoclonal antibodies, single antibody cells that are capable of indefinite reproduction. In November CAT reported annual results with a drastically reduced pretax loss of £5.1 million, down from £10.2 million. It plans to list on Nasdaq this year.